HilleVax, Inc. (NASDAQ:HLVX) COO Sean Mcloughlin Buys 1,250 Shares

HilleVax, Inc. (NASDAQ:HLVXGet Free Report) COO Sean Mcloughlin acquired 1,250 shares of the stock in a transaction dated Thursday, March 28th. The shares were bought at an average cost of $16.98 per share, for a total transaction of $21,225.00. Following the acquisition, the chief operating officer now owns 1,250 shares in the company, valued at approximately $21,225. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

HilleVax Trading Down 4.2 %

HilleVax stock opened at $15.93 on Tuesday. HilleVax, Inc. has a 52 week low of $9.94 and a 52 week high of $20.22. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The firm has a market capitalization of $791.72 million, a PE ratio of -5.24 and a beta of 0.65. The business’s 50-day simple moving average is $16.27 and its 200-day simple moving average is $14.59.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C increased its position in HilleVax by 20.3% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock worth $53,857,000 after acquiring an additional 675,000 shares during the period. Franklin Resources Inc. increased its holdings in shares of HilleVax by 4.1% during the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock worth $29,635,000 after purchasing an additional 71,938 shares during the period. Vanguard Group Inc. increased its holdings in shares of HilleVax by 27.0% during the 4th quarter. Vanguard Group Inc. now owns 1,464,840 shares of the company’s stock worth $23,511,000 after purchasing an additional 310,973 shares during the period. Braidwell LP raised its position in shares of HilleVax by 16.0% during the third quarter. Braidwell LP now owns 1,449,246 shares of the company’s stock valued at $19,492,000 after buying an additional 200,000 shares during the last quarter. Finally, Catalys Pacific LLC acquired a new stake in HilleVax during the fourth quarter worth about $21,009,000. 86.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of HilleVax in a research note on Thursday, March 21st.

Check Out Our Latest Stock Report on HLVX

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Stories

Insider Buying and Selling by Quarter for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.